おすすめの製品
品質水準
アッセイ
≥95% (HPLC)
フォーム
powder
色
white to off-white
溶解性
DMSO: >20 mg/mL
オーガナイザー
Johnson & Johnson
保管温度
room temp
SMILES記法
C[C@@H](CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2
InChI
1S/C11H16N4O4/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19)/t7-/m0/s1
InChI Key
BMKDZUISNHGIBY-ZETCQYMHSA-N
類似した製品をお探しですか? 訪問 製品比較ガイド
詳細
Dexrazoxane is a member of bis(2,6-dioxopiperazines), that functions as a topoisomerase 2 catalytic inhibitor. Dexrazoxane is a free radical scavenger. It might protect the heart from doxorubicin-associated damage. Dexrazoxane acts as a cardiopulmonary protectant, while treating Hodgkin′s disease (HD). It functions as a chelating agent, which limits the formation of anthracycline-iron complexes. It is used to synthesize antimalarial drugs.
アプリケーション
Dexrazoxane has been used in chromatin remodelling experiments.
生物化学的/生理学的作用
Dexrazoxane is a cardioprotective compound against anthracyclines. It functions by inhibiting topoisomerase II without inducing DNA strand breaks. Dexrazoxane is a + enantiomer of razoxane.
Dexrazoxane is a cardioprotective compound used to counteract the effects of anthracyclines. Dexrazoxane is believed to function as a free radical scanenger.
特徴および利点
This compound is a featured product for Apoptosis research. Click here to discover more featured Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
シグナルワード
Warning
危険有害性情報
危険有害性の分類
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
ターゲットの組織
Respiratory system
保管分類コード
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
引火点(°F)
Not applicable
引火点(℃)
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
Jan Code
D1446-VAR:
D1446-5MG:
D1446-BULK:
D1446-25MG:
この製品を見ている人はこちらもチェック
Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease
Tebbi CK, et al.
Journal of Clinical Oncology, 25(5), 493-500 (2007)
The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia
Lipshultz SE, et al.
The New England Journal of Medicine, 351(2), 145-153 (2004)
Topoisomerase IIβ-mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane
Lyu YL, et al.
Cancer Research, 67(18), 8839-8846 (2007)
J S Whelan et al.
Annals of oncology : official journal of the European Society for Medical Oncology, 26(2), 407-414 (2014-11-26)
Four international study groups undertook a large study in resectable osteosarcoma, which included two randomised controlled trials, to determine the effect on survival of changing post-operative chemotherapy based on histological response. Patients with resectable osteosarcoma aged ≤40 years were treated
Volume Transitions of Isolated Cell Nuclei Induced by Rapid Temperature Increase
Chan CJ, et al.
Biophysical Journal, 112(6), 1063-1076 (2017)
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら(テクニカルサービス)